Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Next Previous
Trial Profile

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adagrasib (Primary) ; Afatinib (Primary) ; Cetuximab (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Appendiceal cancer; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept; Registrational; Therapeutic Use
  • Acronyms KRYSTAL; KRYSTAL-01; KRYSTAL-1
  • Sponsors Mirati Therapeutics

Most Recent Events

  • 30 Apr 2025 Results(n=35) evaluating safety, tolerability and pharmacokinetics of MRTX849 (Adagrasib) in patients with advanced solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 20 Sep 2024 Planned End Date changed from 31 Jan 2026 to 16 Jan 2026.
  • 20 Sep 2024 Planned primary completion date changed from 31 Jul 2025 to 14 Jul 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top